ACVR2A and neoplasm: Moreover, the 60 s kINPen plasma treatment, which reduced absolute lesion and tumor sizes significantly, was the only treatment not showing a reduction in ACVR1B, ACVR2A, CSF1, EGF, EGFR, IL15, and IL6RA when compared to all other treatments in the high dose DBP group.